Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-
negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia …

It is currently assumed that myelofibrosis (MF) originates from acquired mutations that target
the hematopoietic stem cell and induce dysregulation of kinase signaling, clonal …

Purpose The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology
in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis …

Purpose Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and
constitutional symptoms. Patients frequently harbor JAK-STAT activating mutations that are …

Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment
of myelofibrosis (MF) in early-and advanced-phase clinical trials. In 2 recent …

Controversy persists regarding the role of histopathology in the distinction between essential
thrombocythemia (ET) and early-prefibrotic primary myelofi-brosis (PMF) presenting with …

Summary Background: Myeloproliferative neoplasms (MPNs) are frequently identified as an
underlying cause in patients with non‐cirrhotic portal vein thrombosis (PVT). The aim of this …

Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm
characterized by stem cell‐derived clonal myeloproliferation, abnormal cytokine expression …

Abstract The Philadelphia chromosome‐negative (Ph‐) chronic myeloproliferative
neoplasms include the three well‐known clinical entities polycythemia vera (PV), essential …

Established risk factors for thrombosis in essential thrombocythemia (ET) include age (≥ 60
years) and previous vascular events. Recently, also leukocytosis has been proposed in risk …